Chimeric HIV/SIV Polypeptide Trimers as HIV/AIDS Vaccine Candidates
Description of Invention:
The technology describes recombinant chimeric polypeptides of HIV Env in which all or part of the N-terminal portion (85 amino acids) of gp41 is replaced with the corresponding region of SIV. These chimeric polypeptides may be potential HIV/AIDS vaccine candidates. The substitution described above promotes efficient trimerization of the Env protein, which has been found in functional virions to have almost exclusively a trimeric structure. Therefore, by mimicking native HIV structure, the chimeric polypeptides described in this technology could be used as immunogens for the generation of neutralizing antibodies that would bind to native HIV. The chimeric polypeptide that contains only the N-terminal portion of SIV in an HIV-1 background is particularly interesting, because several broadly neutralizing HIV-1 epitopes are present in the C-terminal segment of gp41.
Inventors:
Bernard Moss (NIAID)
Patent Status:
DHHS Reference No. E-356-2003/0 Licensing Status: This technology is no longer available for licensing.
For Additional Information Please Contact: Susan Ano Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5515
Email: anos@mail.nih.gov
Fax: (301) 402-0220
